| Entry |
|
|---|
| Name |
Vanoglipel (USAN) |
|---|
| Formula |
C25H31F2N5O2
|
|---|
| Exact mass |
471.2446
|
|---|
| Mol weight |
471.54
|
|---|
| Structure |
|
|---|
| Efficacy |
Antidiabetic |
|---|
| Comment |
Treatment of metabolic dysfunction-associated steatohepatitis and Type 2 diabetes
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Oleoylethanolamide
GPR119
D13209 Vanoglipel (USAN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 34
1 C8y C 11.8768 -15.8953
2 C8y C 11.8768 -17.3019
3 C8y C 13.0949 -18.0051
4 C8x C 14.3132 -17.3019
5 C8y C 14.3132 -15.8953
6 C8x C 13.0949 -15.1920
7 O2a O 15.5500 -15.1810
8 C1b C 16.7608 -15.8800
9 C1b C 17.9486 -15.1939
10 C1b C 19.1482 -15.8865
11 C1y C 20.3417 -15.1972
12 C1x C 21.5383 -15.8882
13 C1x C 22.7565 -15.1849
14 N1y N 22.7565 -13.7784
15 C1x C 21.5598 -13.0874
16 C1x C 20.3418 -13.7907
17 C8y C 23.9872 -13.0677
18 N5x N 25.2009 -13.7684
19 C8x C 26.4190 -13.0650
20 C8y C 26.4189 -11.6585
21 C8x C 25.2051 -10.9579
22 N5x N 23.9871 -11.6612
23 C1b C 27.6411 -10.9527
24 C1a C 28.8595 -11.6560
25 C8y C 10.6588 -18.0051
26 N5x N 9.3927 -17.4413
27 O2x O 8.4654 -18.4712
28 C8y C 9.1581 -19.6715
29 N5x N 10.5137 -19.3834
30 C1c C 8.5742 -20.9833
31 X F 13.0949 -19.4030
32 X F 10.6893 -15.2095
33 C1a C 7.1463 -21.1332
34 C1a C 9.3928 -22.1103
BOND 37
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 11 12 1
13 12 13 1
14 13 14 1
15 14 15 1
16 15 16 1
17 11 16 1
18 14 17 1
19 17 18 2
20 18 19 1
21 19 20 2
22 20 21 1
23 21 22 2
24 17 22 1
25 20 23 1
26 23 24 1
27 2 25 1
28 25 26 2
29 26 27 1
30 27 28 1
31 28 29 2
32 25 29 1
33 28 30 1
34 3 31 1
35 1 32 1
36 30 33 1
37 30 34 1
|
|---|
